相关论文: CAR T Cells from Code to Clinic: Framing Modeling …

Chimeric Antigen Receptor (CAR) T-cell therapy is an immunotherapy that has recently become highly instrumental in the fight against life-threatening diseases. A variety of modeling and computational simulation efforts have addressed…

Chimeric antigen receptor (CAR) T cell therapy is revolutionizing the treatment of blood cancers. Mathematical models that can predict the effectiveness of immunotherapies such as CAR T are of increasing interest due to their ability to…

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a promising treatment for hematological malignancies, offering a targeted approach to cancer treatment. Understanding the complexities of CAR-T cell therapy within solid tumors…

Immunotherapy has the potential to change the way all cancer types are treated and cured. Cancer immunotherapies use elements of the patient immune system to attack tumor cells. One of the most successful types of immunotherapy is CAR-T…

As an adoptive cellular therapy, Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has shown remarkable success in hematological malignancies, but only limited efficacy against solid tumors. Compared with blood cancers, solid tumors…

The goal of cancer immunotherapy is to boost a patient's immune response to a tumor. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumor microenvironment,…

Chimeric Antigen Receptor T (CAR-T) cell therapy has been proven to be successful against different leukaemias and lymphomas. This paper makes an analytical and numerical study of a mathematical model describing the competition of CAR-T,…

Cellular immunotherapies are one of the mainstream cancer treatments unveiling the power of the patient's immune system to fight tumors. CAR T-cell therapy, based on genetically engineered T cells, has demonstrated significant potential in…

Chimeric antigen receptor (CAR) T-cell based immunotherapy has shown its potential in treating blood cancers, and its application to solid tumors is currently being extensively investigated. For glioma brain tumors, various CAR T-cell…

Immunotherapies have been proven to have significant therapeutic efficacy in the treatment of cancer. The last decade has seen adoptive cell therapies, such as chimeric antigen receptor T-cell (CART-cell) therapy, gain FDA approval against…

Chimeric antigen receptor (CAR) T-cells are T-cells engineered to recognize and kill specific tumor cells. Through their extracellular domains, CAR T-cells bind tumor cell antigens which triggers CAR T activation and proliferation. These…

CAR-T cell therapies have demonstrated significant success in treating B-cell leukemia in children and young adults. However, their effectiveness in treating B-cell lymphomas has been limited. Unlike leukemia, lymphoma often manifests as…

Immunotherapies use components of the patient immune system to selectively target cancer cells. The use of CAR T cells to treat B-cell malignancies --leukaemias and lymphomas-- is one of the most successful examples, with many patients…

One of the barriers to the development of effective adoptive cell transfer therapies (ACT), specifically for genetically engineered T-cell receptors (TCRs), and chimeric antigen receptor (CAR) T-cells, is target antigen heterogeneity. It is…

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in hematological malignancies, yet patient responses remain highly variable and the roles of CD4+ and CD8+ subsets are not fully understood. We present an extended…

T cells are central to the adaptive immune response, capable of detecting pathogenic antigens while ignoring healthy tissues with remarkable specificity and sensitivity. Quantitatively understanding how T cell receptors (TCRs) discriminate…

Acute leukemia is a type of blood cancer with a high mortality rate. Current therapeutic methods include bone marrow transplantation, supportive therapy, and chemotherapy. Although a satisfactory remission of the disease can be achieved,…

We study the dynamics and interactions between combined chemotherapy and chimeric antigen receptor (CAR-T) cells therapy and malignant gliomas (MG). MG is one of the most common primary brain tumor, with high resistance to therapy and…

The long-term efficacy of targeted therapeutics for cancer treatment can be significantly limited by the type of therapy and development of drug resistance, inter alia. Experimental studies indicate that the factors enhancing acquisition of…

Chimeric antigen receptor T-cell (CAR-T) therapy is considered a promising cancer treatment. The dynamic response to this therapy can be broadly divided into a short-term phase, ranging from weeks to months, and a long-term phase, ranging…